Nalaganje...
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...
Shranjeno v:
| izdano v: | J Clin Med |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7564568/ https://ncbi.nlm.nih.gov/pubmed/32911840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092905 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|